Dow Jones
39.308,00 -23,90 (-0,06%) Nasdaq
18.188,30 +159,54 (+0,88%) Nikkei 225
40.727,32 +146,56 (+0,36%) EUR/USD
1,0794 +0,0007 (+0,06%) Bitcoin EUR
55.722,09 -1.765,06 (-3,07%) CMC Crypto 200
1.254,23 -80,68 (-6,04%)
Altimmune, Inc. (ALT)
Dopo ore:
| Chiusura precedente | 6,74 |
| Aperto | 6,77 |
| Denaro | 6,56 x 500 |
| Domanda | 6,62 x 2000 |
| Min-Max giorno | 6,52 - 7,00 |
| Intervallo di 52 settimane | 2,09 - 14,84 |
| Volume | |
| Media Volume | 3.596.101 |
| Capitalizzazione | 467,955M |
| Beta (mensile su 5 anni) | 0,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,60 |
| Prossima data utili | 08 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 20 gen 2017 |
| Stima target 1A | 20,57 |
GlobeNewswireAltimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity, will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th Annual Meeting of the European Associatio
- GlobeNewswire
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Top-line 48-week results from the trial expected Q4 2023GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesi
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Wells Fargo 2023 Healthcare Conference in Everett, MAWednesday, September 6, 2023Fireside chat at 3:45 pm Eastern Time Morgan Stanley 21st Annual Global Healthcare Conference in New York, NYWednesday, September 13, 2023F
